EastGate Biotech Announces Engagement of the Kell Group Limited for Introduction to Various Sources of Funding for Company Initiatives

The Kell Group Limited Served as an Agent for Related-party Advances

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 29, 2017 / EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that it has engaged The Kell Group Limited to serve as an agent for the company for the purposes of introducing various sources of funding to the company including grants, project financing and equity financing. The goal of any financing transactions will be used for company initiatives.

The Kell Group Limited is a private corporation that was established in Canada over 25 years ago and has been actively involved in corporate financing initiatives, the construction development business, private lending for real estate projects and business development consulting. The company is in the process of establishing a multi-million dollar fund in order to directly support their various projects they have both in domestic and international markets.

The Kell Group has already successfully served as an agent for funding with respect to related-party advances to the company.

“We are pleased to be working with a group that has a long standing reputation with a wide financial network,” said Anna Gluskin, CEO of EastGate. “We are looking forward to moving into an exciting stage with some of our developments that have different requirements and funding strategies for which we believe The Kell Group Limited is best suited to assist in these plans and we hope will increase their shareholding position in the company,” concludes Gluskin.

About EastGate Biotech

EastGate Biotech focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. We utilize advanced nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain healthy lives.

Our research and development team are dedicated to providing the best nutraceutical products for your natural comfort, health, and well-being. We invite you to explore the naturally healthy benefits of EastGate Biotech.

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com

SOURCE: EastGate Biotech Corp.

ReleaseID: 473952